Endometrial Cancer Clinical Trials in Orlando, Florida
14 studies are recruiting for endometrial cancer in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cel…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002), Orlando, Florida
- Locations
- 264 in total
- Run by
- Merck Sharp & Dohme LLC
-
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Florida Cancer Specialists - Lake Nona, Orlando, Florida
- Locations
- 20 in total
- Run by
- Terremoto Biosciences Inc.
-
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…
- Stage
- Phase 1
- Ages
- 12 and older
- Site
- Advent Health, Orlando, Florida
- Locations
- 77 in total
- Run by
- PMV Pharmaceuticals, Inc
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sarah Cannon Research Institute - Lake Nona Florida, Orlando, Florida
- Locations
- 26 in total
- Run by
- SystImmune Inc.
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participant…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Research Site, Orlando, Florida
- Locations
- 255 in total
- Run by
- AstraZeneca
-
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida
- Locations
- 6 in total
- Run by
- ArriVent BioPharma, Inc.
-
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- ADVENTHEALTH (Data collection only), Orlando, Florida
- Locations
- 18 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Florida Cancer Specialists, Orlando, Florida
- Locations
- 82 in total
- Run by
- Artios Pharma Ltd
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following pla…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Research Site, Orlando, Florida
- Locations
- 320 in total
- Run by
- AstraZeneca
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Florida Cancer Specialists - Lake Nona, Orlando, Florida
- Locations
- 28 in total
- Run by
- Jazz Pharmaceuticals
-
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This prop…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Orlando Health, Orlando, Florida
- Locations
- 24 in total
- Run by
- Mayo Clinic
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sara Cannon Research Institute Lake Nona, Orlando, Florida
- Locations
- 39 in total
- Run by
- SystImmune Inc.
-
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Dren Investigational Site, Orlando, Florida
- Locations
- 10 in total
- Run by
- Dren Bio
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
- Stage
- Phase 2
- Ages
- 18 to 70
- Site
- Orlando Health, Orlando, Florida
- Locations
- 12 in total
- Run by
- Iovance Biotherapeutics, Inc.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.